We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Henry Schein (HSIC) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Henry Schein (HSIC - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Henry Schein is one of 1160 companies in the Medical group. The Medical group currently sits at #13 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Henry Schein is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for HSIC's full-year earnings has moved 4.5% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, HSIC has moved about 8.6% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 11.1% on average. This means that Henry Schein is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Innoviva (INVA - Free Report) . The stock is up 9.4% year-to-date.
In Innoviva's case, the consensus EPS estimate for the current year increased 20.5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Henry Schein belongs to the Medical - Dental Supplies industry, a group that includes 21 individual stocks and currently sits at #111 in the Zacks Industry Rank. On average, this group has lost an average of 8.4% so far this year, meaning that HSIC is performing better in terms of year-to-date returns.
Innoviva, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 14-stock industry is ranked #107. The industry has moved -2.3% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Henry Schein and Innoviva as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Henry Schein (HSIC) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Henry Schein (HSIC - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Henry Schein is one of 1160 companies in the Medical group. The Medical group currently sits at #13 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Henry Schein is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for HSIC's full-year earnings has moved 4.5% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, HSIC has moved about 8.6% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 11.1% on average. This means that Henry Schein is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Innoviva (INVA - Free Report) . The stock is up 9.4% year-to-date.
In Innoviva's case, the consensus EPS estimate for the current year increased 20.5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Henry Schein belongs to the Medical - Dental Supplies industry, a group that includes 21 individual stocks and currently sits at #111 in the Zacks Industry Rank. On average, this group has lost an average of 8.4% so far this year, meaning that HSIC is performing better in terms of year-to-date returns.
Innoviva, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 14-stock industry is ranked #107. The industry has moved -2.3% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Henry Schein and Innoviva as they attempt to continue their solid performance.